DK1809302T3 - Antisense-modulation af integrin-alfa-4-ekspression - Google Patents
Antisense-modulation af integrin-alfa-4-ekspressionInfo
- Publication number
- DK1809302T3 DK1809302T3 DK05857292.6T DK05857292T DK1809302T3 DK 1809302 T3 DK1809302 T3 DK 1809302T3 DK 05857292 T DK05857292 T DK 05857292T DK 1809302 T3 DK1809302 T3 DK 1809302T3
- Authority
- DK
- Denmark
- Prior art keywords
- expression
- integrin alpha
- antisense modulation
- antisense
- modulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62079204P | 2004-10-20 | 2004-10-20 | |
US64882005P | 2005-01-31 | 2005-01-31 | |
PCT/AU2005/001634 WO2006086821A1 (en) | 2004-10-20 | 2005-10-20 | ANTISENS MODULATION OF INTEGRIN α4 EXPRESSION |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1809302T3 true DK1809302T3 (da) | 2012-11-26 |
Family
ID=36916094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05857292.6T DK1809302T3 (da) | 2004-10-20 | 2005-10-20 | Antisense-modulation af integrin-alfa-4-ekspression |
Country Status (9)
Country | Link |
---|---|
US (1) | US8765700B2 (da) |
EP (1) | EP1809302B1 (da) |
JP (1) | JP2008516991A (da) |
AU (1) | AU2005327506B2 (da) |
CA (1) | CA2584614A1 (da) |
DK (1) | DK1809302T3 (da) |
ES (1) | ES2392449T3 (da) |
NZ (1) | NZ554277A (da) |
WO (1) | WO2006086821A1 (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5988581B2 (ja) * | 2008-06-23 | 2016-09-07 | アンチセンス セラピューティクス リミテッド | アンチセンスオリゴヌクレオチドを用いる多発性硬化症の治療方法 |
WO2011020874A1 (en) | 2009-08-20 | 2011-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
AU2011301712C1 (en) * | 2010-09-17 | 2017-01-05 | Antisense Therapeutics Ltd | Method for reducing the number of certain circulating leukocytes in a human subject |
US9340784B2 (en) | 2012-03-19 | 2016-05-17 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
EP2856377B1 (en) * | 2012-06-01 | 2017-09-27 | Intel Corporation | Identification and execution of subsets of a plurality of instructions in a more secure execution environment |
AU2016259971B2 (en) * | 2015-05-11 | 2021-12-09 | ProGenis Pty Ltd | Multiple sclerosis treatment |
AU2016349954B2 (en) * | 2015-11-05 | 2022-08-25 | Antisense Therapeutics Ltd | Mobilizing leukemia cells |
TWI826365B (zh) | 2017-01-10 | 2023-12-21 | 美商愛羅海德製藥公司 | α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法 |
EP3787639A4 (en) | 2018-05-04 | 2022-02-23 | Antisense Therapeutics Ltd | THERAPEUTIC USES AND PROCESSES |
AU2020286462A1 (en) * | 2019-06-06 | 2022-01-27 | Arrowhead Pharmaceuticals, Inc. | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) |
WO2023039643A1 (en) * | 2021-09-20 | 2023-03-23 | Antisense Therapeutics Ltd | Methods and kits therefor |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4309406A (en) | 1979-07-10 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4309404A (en) | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4704295A (en) | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
EP0260032B1 (en) | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
ATE151467T1 (de) | 1987-11-30 | 1997-04-15 | Univ Iowa Res Found | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene |
US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
AU658562B2 (en) | 1989-10-24 | 1995-04-27 | Isis Pharmaceuticals, Inc. | 2' modified oligonucleotides |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5955589A (en) | 1991-12-24 | 1999-09-21 | Isis Pharmaceuticals Inc. | Gapped 2' modified oligonucleotides |
US5859221A (en) | 1990-01-11 | 1999-01-12 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
ATE167523T1 (de) | 1990-05-11 | 1998-07-15 | Microprobe Corp | Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden |
EP0538194B1 (de) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
JPH08508492A (ja) | 1993-03-30 | 1996-09-10 | スターリング ウィンスロップ インコーポレイティド | 非環式ヌクレオシド類似体及びそれらを含むオリゴヌクレオチド配列 |
DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
EP0733059B1 (en) | 1993-12-09 | 2000-09-13 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5696248A (en) | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
US6083923A (en) | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
US5968826A (en) * | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
DE19860642A1 (de) * | 1998-12-29 | 2000-07-06 | Deutsches Krebsforsch | Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen |
BR0006019A (pt) * | 1999-04-06 | 2001-03-13 | Univ East Carolina | Oligonucleotìdeo de anti-sentido de adenosina baixo, composições, kit & método para tratamento de distúrbios de vias aéreas associados com broncoconstricção, inflamação pulmonar, alergia(s) & depleção de surfactante |
CA2597845A1 (en) * | 2005-02-25 | 2006-08-31 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to il-4r alpha |
-
2005
- 2005-10-20 WO PCT/AU2005/001634 patent/WO2006086821A1/en active Application Filing
- 2005-10-20 DK DK05857292.6T patent/DK1809302T3/da active
- 2005-10-20 ES ES05857292T patent/ES2392449T3/es active Active
- 2005-10-20 US US11/666,001 patent/US8765700B2/en not_active Expired - Fee Related
- 2005-10-20 EP EP05857292A patent/EP1809302B1/en not_active Not-in-force
- 2005-10-20 AU AU2005327506A patent/AU2005327506B2/en not_active Ceased
- 2005-10-20 CA CA002584614A patent/CA2584614A1/en not_active Abandoned
- 2005-10-20 NZ NZ554277A patent/NZ554277A/en not_active IP Right Cessation
- 2005-10-20 JP JP2007537071A patent/JP2008516991A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2008516991A (ja) | 2008-05-22 |
US20090029931A1 (en) | 2009-01-29 |
AU2005327506A1 (en) | 2006-08-24 |
AU2005327506B2 (en) | 2010-07-08 |
EP1809302A1 (en) | 2007-07-25 |
ES2392449T3 (es) | 2012-12-10 |
CA2584614A1 (en) | 2006-08-24 |
EP1809302A4 (en) | 2010-07-14 |
US8765700B2 (en) | 2014-07-01 |
WO2006086821A1 (en) | 2006-08-24 |
NZ554277A (en) | 2010-09-30 |
EP1809302B1 (en) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1809302T3 (da) | Antisense-modulation af integrin-alfa-4-ekspression | |
DK1786472T3 (da) | Antisense-modulering af apolipoprotein B-ekspression | |
DK1802579T3 (da) | Derivater af 3-arylaminopyridin | |
DK3225251T3 (da) | Modulering af pro-neurotrofinaktivitet | |
DE502005006470D1 (de) | Verwendung von sulfonylharnstoffen | |
DK1940465T3 (da) | Ny anvendelse af anti-IL-1beta-antistoffer | |
DK2031063T3 (da) | Modulatorer af duftreceptorer | |
DK1720866T3 (da) | Fremgangsmåde | |
DK1797183T3 (da) | Regulering af onkogener med mikrornas | |
DK1915346T3 (da) | Asymmetrisk katalytisk reduktion af oxcarbazepin | |
DK1992697T3 (da) | Fremstilling af TNFR-Fc | |
DK2041270T3 (da) | Fremstilling af glycoproteiner | |
DK1938023T3 (da) | Termisk generator af magnetokalorisk materiale | |
DK1898903T3 (da) | Inhibitorer af Akt-aktivitet | |
DK1730476T3 (da) | Simplificeret måling af fluidegenskaber | |
ATE528296T1 (de) | Polymorphe form von 4-ä3-(4- cyclopropancarbonylpiperazin-1-carbonyl)-4- fluorbenzylü-2h-phthalazin-1-on | |
ATE504588T1 (de) | Stabile salze von olanzapin | |
DK1636190T3 (da) | Stabilt krystal af 4-oxoquinolinforbindelse | |
DK2506479T3 (da) | Forbedret anvendelse af underrammer i et cellulært kommunikationssystem | |
DK3525381T3 (da) | Multipleksering af data- og styresymboler | |
DK2219469T3 (da) | Modificering af enzymatisk disponerede proteiner | |
DK1913954T3 (da) | Anvendelse af fibronectins EDA domæne | |
DK1917227T3 (da) | Krystalformer af astaxanthin | |
DK1587542T3 (da) | Anvendelse af anti-CD100-antistoffer | |
DK2111555T3 (da) | Diagnosticering af præeklampsi |